Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:55:48.701Z.
Calculation as of: 2026-10-06T14:55:48.701Z.
Quote observation: 2026-10-06T14:55:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$664.67M
EV/FCF Ratio
13.07x
TTM Avg
10.66x
3Y Avg
30.61x
5Y Avg
30.61x
Market Cap
$654.94M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$692.29M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$708.19M
EV/FCF Ratio
4.38x
TTM Avg
7.12x
3Y Avg
7.74x
5Y Avg
9.53x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $676.72M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $664.67M | 13.07x | 10.66x | 30.61x | 30.61x |
| Helus Pharma Inc. (HELP)vs › | $663.54M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $654.94M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.75M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $692.29M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $699.65M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $640.56M | N/A | 710.97x | 756.83x | 756.83x |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $708.19M | 4.38x | 7.12x | 7.74x | 9.53x |
| Aura Biosciences, Inc. (AURA)vs › | $635.69M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
